New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 22, 2014
07:08 EDTVIVO, EXAS, QDEL, DGX, ABAX, IDXXLife Sciences highlights this week at Canaccord
Canaccord highlighted six diagnostic names that report this week and recommends buying Top Pick IDEXX (IDXX) into the print given strong recurring razor/razorblade sales and consistent organic growth. The analyst expects Hold rated Quest Diagnostics (DGX) to report upside to Street estimates of $1.06/$1.882B, Quidel (QDEL) to have an uneventful report, Exact Sciences (EXAS) to provide an update on numerous catalysts near-term and Abaxis (ABAX) to report earnings below consensus. Lastly, the firm is cautious on Meridian Bioscience (VIVO) following a competitor report last week.
News For IDXX;DGX;EXAS;ABAX;QDEL;VIVO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2015
16:35 EDTQDELQuidel reports Q1 adjusted EPS 30c, consensus 12c
Reports Q1 revenue $61.3M, consensus $61.22M. Reports Q1 GAAP EPS 11c.
07:34 EDTVIVOMeridian Bioscience still sees FY15 EPS 85c-91c, consensus 86c
Subscribe for More Information
07:34 EDTVIVOMeridian Bioscience reaffirms FY15 guidance
07:33 EDTVIVOMeridian Bioscience reports Q2 EPS 24c, consensus 24c
Subscribe for More Information
07:08 EDTDGXQuest Diagnostics backs FY15 adjusted EPS view $4.70-$4.85, consensus $4.78
Subscribe for More Information
07:06 EDTDGXQuest Diagnostics reports Q1 adjusted EPS $1.05, consensus $1.04
Subscribe for More Information
April 22, 2015
15:50 EDTDGXNotable companies reporting before tomorrow's open
Subscribe for More Information
April 21, 2015
08:14 EDTDGXQuest Diagnostics and Inserm launch BRCA Share initiative
Quest Diagnostics (DGX) and Inserm, the French National Institute of Health and Medical Research institution, launched BRCA Share, a novel datashare initiative they co-founded to provide scientists and laboratory organizations around the world with open access to BRCA1 and BRCA2 genetic data. The program's goal is to accelerate research on BRCA gene mutations, particularly variants of uncertain significance, to improve the ability of clinical laboratory diagnostics to predict which individuals are at risk of developing hereditary breast and ovarian cancers. Laboratory Corporation of America Holdings (LH) is the first participant in the initiative, which is structured as a user group. B
06:40 EDTDGXStart-up to offer saliva test for breast cancer susceptibility, NY Times says
Subscribe for More Information
April 15, 2015
12:32 EDTDGXFocus Diagnostics announced FDA clearance for Simplexa Group A Strep Direct Kit
Subscribe for More Information
April 13, 2015
08:01 EDTEXASExact Sciences says Cologuard receives coverage by several health plans in Q1
Since the start of 2015, several insurers began covering Cologuard as a noninvasive colon cancer screening test. In addition to several smaller regional providers, insurance plans covering the test now include: Anthem Blue Cross and Blue Shield, a leading national health plan with more than 37 million members across 14 states, Tufts Health Plan, with more than 1 million members across Massachusetts and Rhode Island and ranked the number one health plan for quality in the country for its Commercial plans and its Medicaid plans, CareFirst BlueCross BlueShield PPO, with 2.3 million eligible members across Maryland, District of Columbia and Northern Virginia, Excellus BCBS WNY, with more than 1.4 million members across Western New York and Dean Health Plan, insuring more than 272,037 members across Central Wisconsin.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use